T3630

Relugolix (RVT-601) is an orally available, non-peptide gonadotropin-releasing hormone (GnRH or luteinizing hormone-releasing hormone (LHRH)) antagonist, with potential antineoplastic activity. Relugolix competitively binds to and blocks the GnRH receptor in the anterior pituitary gland, which both prevents GnRH binding to the GnRH receptor and inhibits the secretion and release of both luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone from Leydig cells in the testes. Since testosterone is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation.

Uridine-5'-monophosphate (UMP) is a ribonucleotide.1It is formedviadecarboxylation of orotidine-5'-monophosphate (5'-OMP) by OMP decarboxylase. UMP is further phosphorylated by UMP-CMP kinase to form UDP and UTP during nucleic acid biosynthesis. Formulations containing UMP have been used as dietary supplements. 1.Berg, J.M., Tymoczko, J.L., and Stryer, L.Nucleotide BiosynthesisBiochemistry(2002)

PluriSIn #2 acts as a selective transcriptional inhibitor of topoisomerase II α (TOP2A) and effectively eliminates undifferentiated human pluripotent stem cells (hPSCs)[1].

PR-104 is a highly specific hypoxia-activated agent that cross-links DNA, enabling its application in various tumor xenograft models. Functioning as a pre-prodrug of nitrogen mustard, PR-104 undergoes efficient conversion to the dinitrobenzamide mustards alcohol form, known as PR-104A[1].

Psammaplin A, a marine metabolite, functions as a robust inhibitor of HDAC and DNA methyltransferases, displaying notable potency and selectivity as a DAC1 inhibitor, with an IC50 value of 0.9 nM. It exhibits antimicrobial effects against Gram-positive bacteria and inhibits DNA synthesis and DNA gyrase activity, demonstrating antitumor activity [1][2].

FT206 is a carboxamide inhibitor of ubiquitin-specific protease[1].

mTOR inhibitor WYE-28 (compound 28) is an mTOR inhibitor (IC50 = 0.08 nM) and PI3Kα inhibitor (IC50 = 6 nM) with a half-life of 13 minutes in nude mouse microsomes.

PF-06843195 is a potent and selective PI3Kα inhibitor that binds to the active site of PI3Kα and prevents it from catalyzing the conversion of PIP2 to PIP3, thereby inhibiting the activation of AKT, with anti-tumor activity in vitro and in vivo.

AZ2 is a highly selective, active PI3Kγ inhibitor (pIC50=9.3) for use in inflammatory and immune disorders.

Relugolix-D6 is a deuterated compound of Relugolix. Relugolix (T3630) has a CAS number of 737789-87-6. Relugolix (T3630) is an orally available, non-peptide gonadotropin-releasing hormone (GnRH or luteinizing hormone-releasing hormone (LHRH)) antagonist, with potential antineoplastic activity. Relugolix (T3630) competitively binds to and blocks the GnRH receptor in the anterior pituitary gland, which both prevents GnRH binding to the GnRH receptor and inhibits the secretion and release of both luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone from Leydig cells in the testes. Since testosterone is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation.